医学
背景(考古学)
药品
疾病
单克隆抗体
临床试验
药物开发
免疫学
生物信息学
抗体
药理学
内科学
生物
古生物学
作者
Zhiwen Huang,Zachary Braunstein,Jun Chen,Yingying Wei,Xiaoquan Rao,Lingli Dong,Jixin Zhong
出处
期刊:Pharmacological Reviews
[American Society for Pharmacology & Experimental Therapeutics]
日期:2024-04-15
卷期号:: PHARMREV-001084
标识
DOI:10.1124/pharmrev.123.001084
摘要
In the era of precision medicine, Antibody-Drug Conjugates (ADCs) have emerged as a cutting-edge therapeutic strategy. These innovative compounds combine the precision of monoclonal antibodies with the potent cell-killing or immune-modulating abilities of attached drug payloads. This unique strategy not only reduces off-target toxicity but also enhances the therapeutic effectiveness of drugs. Beyond their well-established role in oncology, ADCs are now showing promising potential in addressing the unmet needs in the therapeutics of rheumatic diseases. Rheumatic diseases, a diverse group of chronic autoimmune diseases with varying etiologies, clinical presentations, and prognoses, often demand prolonged pharmacological interventions, creating a pressing need for novel, efficient and low-risk treatment options. ADCs, with their ability to precisely target the immune components, have emerged as a novel therapeutic strategy in this context. This review will provide an overview of the core components and mechanisms behind ADCs, a summary of the latest clinical trials of ADCs for the treatment if rheumatic diseases, as well as a discussion on the challenges and future prospects faced by the development of next-generation ADCs. Significance Statement There is a lack of efficient and low-risk targeted therapeutics for rheumatic diseases. Antibody-drug conjugates, a class of cutting-edge therapeutic drugs, have emerged as a promising targeted therapeutic strategy for rheumatic disease. While there is limited literature summarizing the progress of antibody-drug conjugates in the field of rheumatic disease, updating the advancements in this area provides novel insights into the development of novel anti-rheumatic drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI